HRP20030609A2 - Use of il-18 inhibitors for the treatment and/or prevention of heart disease - Google Patents

Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Info

Publication number
HRP20030609A2
HRP20030609A2 HR20030609A HRP20030609A HRP20030609A2 HR P20030609 A2 HRP20030609 A2 HR P20030609A2 HR 20030609 A HR20030609 A HR 20030609A HR P20030609 A HRP20030609 A HR P20030609A HR P20030609 A2 HRP20030609 A2 HR P20030609A2
Authority
HR
Croatia
Prior art keywords
inhibitors
prevention
treatment
heart disease
heart
Prior art date
Application number
HR20030609A
Other languages
English (en)
Inventor
Dinarello Charles
Pomerantz Benjamin
Rezinkov Leonid
Harken Alden
Chvatchko Yolande
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of HRP20030609A2 publication Critical patent/HRP20030609A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HR20030609A 2001-01-29 2003-07-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease HRP20030609A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29
PCT/EP2002/000844 WO2002060479A1 (en) 2001-01-29 2002-01-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Publications (1)

Publication Number Publication Date
HRP20030609A2 true HRP20030609A2 (en) 2005-06-30

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030609A HRP20030609A2 (en) 2001-01-29 2003-07-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Country Status (32)

Country Link
US (1) US20040234523A1 (pt)
EP (1) EP1355668B1 (pt)
JP (2) JP4860897B2 (pt)
KR (1) KR100857376B1 (pt)
CN (1) CN1326562C (pt)
AR (1) AR032422A1 (pt)
AT (1) ATE380558T1 (pt)
BG (1) BG66483B1 (pt)
BR (1) BR0206819A (pt)
CA (1) CA2435466C (pt)
CY (1) CY1107203T1 (pt)
CZ (1) CZ305653B6 (pt)
DE (1) DE60224004T2 (pt)
DK (1) DK1355668T3 (pt)
EA (2) EA010180B1 (pt)
EE (1) EE05534B1 (pt)
ES (1) ES2295332T3 (pt)
HK (1) HK1062810A1 (pt)
HR (1) HRP20030609A2 (pt)
HU (1) HU229164B1 (pt)
IL (2) IL157024A0 (pt)
ME (1) ME00549B (pt)
MX (1) MXPA03006776A (pt)
NO (1) NO331083B1 (pt)
PL (1) PL213568B1 (pt)
PT (1) PT1355668E (pt)
RS (1) RS51125B (pt)
SI (1) SI1355668T1 (pt)
SK (1) SK287620B6 (pt)
UA (1) UA80676C2 (pt)
WO (1) WO2002060479A1 (pt)
ZA (1) ZA200305439B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
EP2357002A1 (en) 2000-10-11 2011-08-17 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
EP1891088B1 (en) 2005-06-10 2011-10-19 Ares Trading S.A. Process for the purification of il-18 binding protein
JP5968590B2 (ja) 2007-11-05 2016-08-10 ケーシーアイ ライセンシング インコーポレイテッド 創面切除のための組織の同定
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP3041864B1 (en) * 2013-09-05 2021-07-21 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
AU2016227644B2 (en) * 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
IL125190A (en) * 1996-09-12 2003-01-12 Idun Pharmaceuticals Inc Tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes and pharmaceutical compositions containing the same
WO1998024804A2 (en) * 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
CN1269722A (zh) * 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
WO2000055114A1 (en) * 1999-03-16 2000-09-21 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
CN1176941C (zh) * 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
PT1278540E (pt) * 2000-05-05 2008-07-03 Inst Nat Sante Rech Med Utilização de inibidores da il-18 para o tratamento e/ou prevenção de aterosclerose
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CZ20032335A3 (en) 2004-07-14
SI1355668T1 (sl) 2008-06-30
YU57803A (sh) 2006-05-25
CZ305653B6 (cs) 2016-01-27
ATE380558T1 (de) 2007-12-15
CN1326562C (zh) 2007-07-18
WO2002060479A1 (en) 2002-08-08
BR0206819A (pt) 2004-02-03
JP2004522748A (ja) 2004-07-29
US20040234523A1 (en) 2004-11-25
DK1355668T3 (da) 2008-05-05
UA80676C2 (en) 2007-10-25
JP4860897B2 (ja) 2012-01-25
IL157024A0 (en) 2004-02-08
EA200501549A1 (ru) 2006-04-28
IL157024A (en) 2014-02-27
BG108128A (bg) 2004-11-30
EA006767B1 (ru) 2006-04-28
RS51125B (sr) 2010-10-31
KR100857376B1 (ko) 2008-09-05
BG66483B1 (bg) 2015-03-31
MXPA03006776A (es) 2003-10-24
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
EE200300328A (et) 2003-10-15
CN1499982A (zh) 2004-05-26
HUP0303306A3 (en) 2005-12-28
NO20033228D0 (no) 2003-07-16
CA2435466A1 (en) 2002-08-08
HK1062810A1 (en) 2004-11-26
NO331083B1 (no) 2011-10-03
SK10892003A3 (sk) 2004-02-03
EP1355668A1 (en) 2003-10-29
PL213568B1 (pl) 2013-03-29
DE60224004D1 (de) 2008-01-24
EA010180B1 (ru) 2008-06-30
PT1355668E (pt) 2008-01-04
EP1355668B1 (en) 2007-12-12
CA2435466C (en) 2012-04-03
PL366802A1 (en) 2005-02-07
HUP0303306A2 (hu) 2004-01-28
HU229164B1 (en) 2013-09-30
CY1107203T1 (el) 2012-11-21
ME00549B (me) 2011-10-10
AR032422A1 (es) 2003-11-05
ES2295332T3 (es) 2008-04-16
EA200300844A1 (ru) 2003-12-25
DE60224004T2 (de) 2009-07-23
NO20033228L (no) 2003-09-26
EE05534B1 (et) 2012-04-16
JP2009102354A (ja) 2009-05-14
ZA200305439B (en) 2004-07-15

Similar Documents

Publication Publication Date Title
SI1487541T1 (sl) Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
HUP0401127A3 (en) Treatment and diagnosis of macrophage disease
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
EP1455778A4 (en) METHODS OF TREATING PERIPHERAL NEUROVASCULAR MALAYS
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
PL372928A1 (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
GB0213869D0 (en) The treatment of pain
EP1406648A4 (en) USE OF ANGIOTENSIN I DERIVATIVE AGENT FOR THE TREATMENT AND PREVENTION OF INFECTIOUS HEART DAMAGE AND DISEASES
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
EP1409734A4 (en) DIAGNOSIS AND TREATMENT OF CANCER
GB0101146D0 (en) Treatment of skin conditions
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EP1669085A4 (en) THERAPEUTIC AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE
AU2002365654A8 (en) Treatment of diseases via the skin
GB0108622D0 (en) Treatment and prevention of tissue damage
GB0121046D0 (en) The diagnosis and treatment of airways disease
EP1463525A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMOR

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20041206

Year of fee payment: 4

A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: LABORATOIRES SERONO SA, CH

ODBI Application refused